US Patent No: 7,070,996

Number of patents in Portfolio can not be more than 2000

Production of cultured human mast cells and basophils for high throughput small molecule drug discovery

Stats

ALSO PUBLISHED AS: 20030077824
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated populations contain a uniform population of a size suitable for use in high throughput screening methods, for example, screening for agents that alter exocytosis. The invention includes screening the proliferated populations with at least one candidate bioactive agent, and evaluating the cells to detect a cell with an altered phenotype. The invention also includes isolating a candidate bioactive agent that causes the altered phenotype. Additionally, cells formed according to the described methods are also encompassed by the invention.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
RIGEL PHARMACEUTICALS, INC.SOUTH SAN FRANCISCO, CA243

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Rossi, Alexander B San Francisco, CA 35 583

Cited Art

Patent Info (Count) # Cites Year
 
CELLDEX THERAPEUTICS, INC. (3)
5,554,512 Ligands for flt3 receptors 27 1994
5,843,423 Methods of stimulating hematopoietic cells with flt3-ligand 47 1997
6,190,655 Methods of using Flt-3 ligand for exogenous gene transfer 12 1998
 
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (1)
6,225,044 Method for gene transfer into cells activated from a quiescent state 4 1999
 
DANA-FARBER CANCER INSTITUTE, INC. (1)
4,559,310 Assay methods and systems utilizing mast cell clones 14 1983
 
NORTHWESTERN UNIVERSITY (1)
6,261,841 Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells 3 2000

Patent Citation Ranking

Forward Cites

Patent Info (Count) # Cites Year
 
RIGEL PHARMACEUTICALS, INC. (11)
7,557,210 2,4-pyrimidinediamine compounds and their uses 16 2003
8,178,671 Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds 1 2004
7,521,560 2-substituted quinoline compounds and their uses 0 2005
7,435,814 2,4-Pyrimidinediamine compounds and their uses 10 2005
7,582,648 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 6 2006
7,452,879 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds 13 2006
7,659,280 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 4 2007
7,655,797 Intermediates for making 2,4-pyrimidinediamine compounds 5 2008
7,803,939 2,4-pyrimidinediamine compounds and their uses 4 2008
8,334,296 2,4-pyrimidinediamine compounds and their uses 0 2008
8,314,093 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases 0 2009

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 4, 2014
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 4, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00